RB-ADSC for mild-to-moderate Alzheimer's disease
phase 2drug program · high · Thu Jan 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Treat mild to moderate Alzheimer's disease and evaluate whether repeated intracerebroventricular dosing improves cognitive performance versus placebo while continuing safety evaluation.
Autologous adipose-derived stem cell product from the participant's own adipose tissue, delivered intracerebroventricularly every 2 months for up to 6 total doses; Phase 2 includes placebo control with crossover option.
Phase 2 clinical trial record published 2025-11-01; Phase 1b extension trial for repeat injections in prior RB-ADSC-02 participants published 2026-01-01.
Phase 2 record references positive preliminary results seen in Phase 1, but no detailed efficacy or safety results are supplied in the provided material.